HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).

被引：0
|
作者：
Mateos, Maria-Victoria
Oriol, Albert
Larocca, Alessandra
Blade, Joan
Cavo, Michele
Rodriguez Otero, Paula
Leleu, Xavier
Hiemenz, John W.
Hassoun, Hani
Touzeau, Cyrille
Alegre, Adrian
Paner, Agne
Maisel, Christopher
Mazumder, Amitabha
Raptis, Anastasios
Harmenberg, Johan
Zavisic, Stojan
Thuresson, Sara
Ohman, Oskar
Richardson, Paul G.
机构：
[1] Univ Hosp Salamanca, Canc Res Ctr IBMCC USAL CSIC, IBSAL, Salamanca, Spain
[2] Hosp Badalona Germans Trias & Pujol, Inst Invest Leucemia Josep Carreras, Badalona, Spain
[3] Hosp Badalona Germans Trias & Pujol, Inst Catela Oncol, Badalona, Spain
[4] AOU Citta Salute & Sci Torino SC, Ematol u, Torin, Italy
[5] Hosp Clin Barcelona, Serv Oncohematol, Barcelona, Spain
[6] St Orsola Marcello Malpighi Hosp, Bologna, Italy
[7] Clin Univ Navarra Pamploma, Navarra, Spain
[8] CHU Poitiers, Poitiers, France
[9] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
[10] Mem Sloan Kettering Canc, Myeloma Serv, Dept Med, New York, NY USA
[11] Ctr Hosp Univ, Nantes, France
[12] Hosp Univ La Princesa, Madrid, Spain
[13] Assoc Med Onc, Bolingbrook, IL USA
[14] Baylor Scott & White Charles A Sammons Canc Ctr, Dallas, TX USA
[15] Oncol Inst Hope & Innovat, Glendale, CA USA
[16] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[17] Oncopeptides AB, Stockholm, Sweden
[18] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20570
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone
    Richardson, Paul G.
    Larocca, Alessandra
    Leleu, Xavier
    Oriol, Albert
    Paner, Agne
    Otero, Paula Rodriguez
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Maisel, Christopher
    Mateos, Maria-Victoria
    Mazumder, Amitabha
    Strang, Peter
    Ohman, Oskar
    Harmenberg, Johan
    Zavisic, Stojan
    Blade, Joan
    BLOOD, 2019, 134
  • [32] ANCHOR (OP-104): Melflufen Plus Dexamethasone and Bortezomib in Relapsed/Refractory Multiple Myeloma (RRMM)-Optimal Dose, Updated Efficacy and Safety Results
    Hajek, Roman
    Pour, Ludek
    Granell, Miquel
    Maisnar, Vladimir
    Richardson, Paul G.
    Norin, Stefan
    Sydvander, Malin
    Obermueller, Jakob
    Ocio, Enrique M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S425 - S426
  • [33] Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
    Schjesvold, Fredrik
    Dimopoulos, Meletios A.
    Delimpasi, Sosana
    Robak, Pawel
    Coriu, Daniel
    Legiec, Wojciech Maciej
    Pour, Ludek
    Spicka, Ivan
    Masszi, Tamas
    Doronin, Vadim Anatolievich
    Minarik, Jiri
    Salogub, Galina
    Alexeeva, Yulia
    Lazzaro, Antonio
    Maisnar, Vladimir
    Mikala, Gabor
    Norin, Stefan
    Thuresson, Marcus
    Bergan, Anna
    Obermuller, Jakob
    Hajek, Roman
    Mateos, Maria-Victoria
    Richardson, Paul G.
    Sonneveld, Pieter
    BLOOD, 2023, 142
  • [34] ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Up-dated Efficacy and Safety
    Ocio, Enrique M.
    Efebera, Yvonne A.
    Hajek, Roman
    Granell, Miquel
    Maisnar, Vladimir
    Straub, Jan
    Eveillard, Jean-Richard
    Karlin, Lionel
    Ribrag, Vincent
    Mateos, Maria-Victoria
    Oriol, Albert
    Sydvander, Malin
    Norin, Stefan
    Mannikko, Sofia
    Pour, Ludek
    BLOOD, 2020, 136
  • [35] OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
    Schjesvold, Fredrik
    Dimopoulos, Meletios-Athanasios
    Delimpasi, Sosana
    Robak, Pawel
    Coriu, Daniel
    Legiec, Wojciech
    Pour, Ludek
    Spicka, Ivan
    Masszi, Tamas
    Doronin, Vadim
    Minarik, Jiri
    Salogub, Galina
    Alexeeva, Yulia
    Lazzaro, Antonio
    Maisnar, Vladimir
    Mikala, Gabor
    Moody, Victoria
    Thuresson, Marcus
    Byrne, Catriona
    Harmenberg, Johan
    Hajek, Roman
    Mateos, Maria-Victoria
    Richardson, Paul G.
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S32 - S32
  • [36] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Jakubowiak, Andrzej J.
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Tsao, Claire
    Lynch, Mark John
    Bleickardt, Eric W.
    Jou, Ying-Ming
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Knop, Stefan
    Lonial, Sagar
    Richardson, Paul
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, Albert
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    Van De Donk, Niels W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 171 - 171
  • [38] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Richardson, Paul G.
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, A.
    Knop, Stefan
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David S.
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S9 - S9
  • [39] ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update
    Pour, Ludek
    Efebera, Yvonne A.
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Norkin, Maxim
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Sydvander, Malin
    Ocio, Enrique
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S326 - S327
  • [40] Melflufen Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Exposed and/or Refractory to Prior Alkylators - A Pooled Analysis of the O-12-M1 and HORIZON Studies
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Leleu, Xavier
    Nadeem, Omar
    Hiemenz, John
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Richardson, Paul
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S8 - S9
12345